PCRX Finance

PharmaCorp Rx Inc. Announces New Credit Facilities With CIBC and Unveils Pharmacist Co-Ownership Financing Initiative

Published August 13, 2025 at 09:00 PM

SASKATOON, Saskatchewan, Aug. 13, 2025 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) is pleased to announce that it has entered into a credit agreement with Canadian Imperial Bank of Commerce (“CIBC”) providing the Corporation with up to $20,500,000 of committed credit facilities (the “Credit Facilities”), plus a $10,000,000 accordion feature and a $1,000,000 Visa credit facility. The Credit Facilities will support PharmaCorp’s acquisition strategy and the expansion of its acquisition and operating platforms.

Related Questions

What specific acquisition targets is PharmaCorp planning to pursue with the new credit facilities? Will the credit facilities provide sufficient capital to fund the company's expansion plans without requiring additional equity raises? What are the potential risks if PharmaCorp fails to meet the credit facility covenants or if acquisition integration does not go as planned? How will the market likely react to this announcement in terms of trading volume and price movement? How will the $20.5M credit facilities and additional accordion and Visa facilities affect PharmaCorp's liquidity and balance sheet? Will the increased leverage from these facilities dilute existing shareholders or impact earnings per share? How does the cost of the new credit facilities (interest rates, covenants) compare to PharmaCorp's existing debt and to peers in the sector? What is the expected timeline for deploying the $10M accordion feature and the $1M Visa credit facility? How might the financing initiative for pharmacist co‑ownership influence the company's growth prospects and valuation? Does the involvement of CIBC as a lender signal any strategic partnership or preferential terms that could benefit PharmaCorp?